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The majority of GWAS of T2D susceptibility have been undertaken in 
populations of European ancestry1–5, predominantly because of exist-
ing infrastructure, sample availability and relatively poor coverage 
by many of the earliest genome-wide genotyping arrays of common 
genetic variation in other major ethnic groups6. However, populations 
of European ancestry constitute only a subset of human genetic vari-
ation and are thus insufficient to fully characterize T2D risk variants 
in other ethnic groups. Furthermore, the latest genome-wide geno-
typing arrays are less biased toward Europeans, and more recent T2D 
GWAS have been performed with great success in populations from 
other ancestry groups, including east Asians7–12, south Asians13,14, 
Mexicans and Mexican Americans15 and African Americans16. These 
studies have provided initial evidence of overlap in T2D susceptibility 
loci between ancestry groups, as well as for coincident risk alleles 
at lead SNPs across diverse populations17,18. These observations are 
consistent with a model in which the underlying causal variants at 
many of these loci are shared across ancestry groups and thus arose 
before migration of the human population out of Africa. Under such a 
model, we would expect to improve the power to detect new suscepti-
bility loci for the disease and enhance the fine-mapping resolution of 
causal variants by combining GWAS across ancestry groups through 
trans-ethnic meta-analysis because of increased sample size and dif-
ferences in the structure of linkage disequilibrium (LD) between such 
diverse populations6,19–21.
In this study, we aggregated published meta-analyses of GWAS in a 
total of 26,488 cases and 83,964 controls from populations of European, 
east Asian, south Asian and Mexican and Mexican American 
ancestry5,11,13,15. T2D GWAS from populations of African ancestry, 
which would be expected to provide the greatest potential for fine 
mapping of common causal variants because of less extensive LD than 
other ethnic groups6, were not accessible for inclusion in our analy-
ses. With these data, we aimed to (i) assess the evidence for excess 
concordance in the direction of effect of T2D risk alleles across ances-
try groups; (ii) identify new T2D susceptibility loci through trans- 
ethnic meta-analysis and subsequent validation in an additional 
21,491 cases and 55,647 controls of European ancestry; and 
(iii) evaluate the improvements in the fine-mapping resolution of 
common variant association signals in established T2D susceptibility 
loci through trans-ethnic meta-analysis despite the lack of GWAS 
from populations of African ancestry.
RESULTS
Study	overview
We considered published meta-analyses of GWAS of T2D susceptibil-
ity from four major ethnic groups (Supplementary Tables 1 and 2) 
undertaken by (i) the DIAbetes Genetics Replication and Meta-analysis 
(DIAGRAM) Consortium5 (European ancestry; 12,171 cases and 
56,862 controls); (ii) the Asian Genetic Epidemiology Network T2D 
(AGEN-T2D) Consortium11 (east Asian ancestry; 6,952 cases and 
11,865 controls); (iii) the South Asian T2D (SAT2D) Consortium13 
(south Asian ancestry; 5,561 cases and 14,458 controls); and 
(iv) the Mexican American T2D (MAT2D) Consortium15 (Mexican 
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and Mexican American ancestry; 1,804 cases and 779 controls). 
We obtained association summary statistics from the four available 
ethnic-specific meta-analyses, each of which was imputed at up to 
2.5 million autosomal SNPs from Phase II/III HapMap22,23, to provide 
a uniform catalog of common genetic variation, defined by a minor 
allele frequency (MAF) of at least 5%, across ancestry groups (Online 
Methods). We then combined these association summary statistics 
across ancestry groups in a trans-ethnic fixed-effects meta-analysis 
(Online Methods).
Concordance	of	T2D	risk	alleles	across	ancestry	groups
We began by evaluating heterogeneity in allelic effects (i.e., discord-
ance in the direction and/or magnitude of odds ratios) between 
ancestry groups at 69 established autosomal T2D susceptibility loci. 
We assessed the evidence for heterogeneity at previously reported 
lead SNPs on the basis of Cochran’s Q statistics from the trans-ethnic 
meta-analysis (Online Methods and Supplementary Table 3). We 
observed nominal evidence of heterogeneity (Bonferroni correction, 
PQ < 0.05/69 = 0.00072) at the previously reported lead SNP at just 
three loci. At TCF7L2 (rs7903146, PQ = 0.00055), the odds ratio is 
the largest in populations of European ancestry, although the risk 
allele has a consistent direction of effect across ethnicities. At PEPD 
(rs3786897, PQ = 0.00055) and KLF14 (rs13233731, PQ = 0.00064), 
however, the association signals are apparently specific to the popula-
tions of east Asian and European ancestry, respectively, despite the 
fact that the reported lead SNPs are common in all ethnic groups. 
We also observed that at 52 previously reported lead SNPs passing 
quality control in each of the four ethnic-specific meta-analyses, 
34 showed the same direction of effect across all ancestry groups 
(65.4% compared with 12.5% expected by chance, binomial test 
P < 2.2 × 10−16). The strong evidence of homogeneity in allelic effects 
across ancestry groups at the majority of the previously reported 
lead SNPs argues against the ‘synthetic association’ hypothesis24. 
It is improbable that GWAS signals at most of the established T2D 
susceptibility loci reflect unobserved lower-frequency causal alleles 
with larger effects because (i) rare variants are unlikely to have arisen 
before migration of the human population out of Africa and are thus 
not expected to be widely shared across diverse populations25; and 
(ii) patterns of LD with these variants are anticipated to be highly 
variable between ethnicities.
To gain insights into the potential for the discovery of new T2D 
susceptibility loci through fixed-effects trans-ethnic meta-analysis, 
we next assessed the genome-wide coincidence of risk alleles 
(i.e., direction of effect) across ancestry groups after exclusion of 
the 69 established autosomal GWAS signals, which we defined as 
mapping within 500 kb of the previously reported lead SNPs (Online 
Methods). First we identified independent SNPs (separated by at least 
500 kb) with nominal evidence of association (P ≤ 0.001) with T2D 
from the European ancestry meta-analysis. By aligning the effect 
of the T2D risk allele from the European meta-analysis into the 
other ancestry groups, we observed evidence of a significant excess 
in directional concordance between ethnicities: 57.0% with east 
Asian populations (binomial test P = 0.0077); 55.4% with south Asian 
populations (binomial test P = 0.032); and 56.6% with Mexican and 
Mexican American populations (binomial test P = 0.010). Using 
the same approach, we also observed an excess of consistency in 
the direction of effect between ethnicities at independent SNPs 
demonstrating weaker evidence of T2D association (0.001 < P ≤ 0.01) 
from the European meta-analysis (Table 1). In contrast, when we 
considered independent SNPs with no evidence of association 
(P > 0.5) with T2D, there was no enrichment in coincident risk alleles 
across ethnic groups. We repeated this analysis by identifying T2D 
risk alleles at SNPs with nominal evidence of association in each of 
the east Asian, south Asian and Mexican and Mexican American 
meta-analyses and assessing concordance in the direction of effect 
in each of the other ancestry groups (Supplementary Table 4). The 
evidence for an excess in concordance between T2D risk alleles across 
ethnicities was not as strong, particularly for the Mexican and Mexican 
American meta-analysis. However, this finding presumably reflects 
reduced power due to smaller sample sizes, and there was still signifi-
cant over-representation of alleles with the same direction of effect 
across ancestry groups at SNPs with nominal evidence of association 
with the disease.
Seven	new	T2D	susceptibility	loci	at	genome-wide	significance
The observations from our concordance analyses are consistent with 
a long tail of common T2D susceptibility variants with effects that are 
decreasing in magnitude but that are homogeneous across ancestry 
groups. Under such a model, we would expect these variants to be 
amenable to discovery by trans-ethnic fixed-effects meta-analyses. In 
this study, by aggregating the published ethnic-specific meta-analyses 
under a fixed-effects model, we identified 33 independent SNPs 
(separated by at least 500 kb) with suggestive evidence of associa-
tion (P < 10−5) at loci not previously reported for T2D susceptibility 
in any ancestry group (Supplementary Table 5 and Supplementary 
Fig. 1). By convention, we labeled loci according to the gene nearest 
to the lead SNP unless a compelling biological candidate mapped 
nearby. It is essential to validate partially imputed association sig-
nals with direct genotyping. Consequently, we carried forward these 
33 loci for in silico follow up in a meta-analysis of an additional 21,491 
cases and 55,647 controls of European ancestry5 genotyped with the 
Metabochip (Online Methods and Supplementary Tables 1 and 2). 
This custom array was designed to facilitate cost-effective replication 
of nominal associations for T2D and other metabolic and cardio-
vascular traits26. However, it provides relatively limited coverage of 
common genetic variation genome wide, with the result that the lead 
table 1 concordance in the direction of effect of t2D risk alleles
Trans-ethnic concordance
European into east Asian European into south Asian European into Mexican and Mexican American
European ancestry meta-
analysis P value threshold
Concordant SNPs/ 
total SNPs % Binomial test P
Concordant SNPs/ 
total SNPs % Binomial test P
Concordant SNPs/ 
total SNPs % Binomial test P
P ≤ 0.001 180/316 57.0 0.0077 175/316 55.4 0.032 179/316 56.6 0.010
0.001 < P ≤ 0.01 877/1,624 54.0 0.00068 861/1,624 53.0 0.0080 886/1,624 54.6 0.00013
0.01 < P ≤ 0.5 2,556/5,053 50.6 0.21 2,604/5,053 51.5 0.015 2,588/5,053 51.2 0.043
0.5 < P ≤ 1 2,535/5,039 50.3 0.34 2,532/5,039 50.2 0.37 2,519/5,039 50.0 0.51
The T2D risk alleles shown were identified in a meta-analysis of a GWAS of European ancestry (12,171 cases and 56,862 controls) along with those identified in meta-analyses 
of GWAS of east Asian (6,952 cases and 11,865 controls), south Asian (5,561 cases and 14,458 controls) and Mexican and Mexican American (1,804 cases and 779 controls) 
ancestry after exclusion of the 69 established autosomal susceptibility loci and defined as mapping within 500 kb of the previously reported lead SNP.
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SNPs, or close proxies (CEU r2 > 0.6 from Phase II HapMap), were 
present at just 24 of the loci. We also identified poorer proxies at two 
additional loci, rs9505118 (SSR1-RREB1, CEU r2 = 0.26, P = 1.9 × 
10−6) and rs4275659 (MPHOSPH9, CEU r2 = 0.48, P = 5.5 × 10−6), 
which nonetheless demonstrated only marginally weaker association 
signals than the lead SNPs (SSR1-RREB1, rs9502570, P = 5.7 × 10−7; 
MPHOSPH9, rs1727313, P = 1.2 × 10−6). Given that these variants 
met our threshold for follow up from the trans-ethnic meta-analysis, 
we also considered them for validation.
By combining association summary statistics from the trans- 
ethnic discovery and European ancestry validation meta-analyses, 
SNPs at seven loci achieved genome-wide significance (combined 
meta-analysis P < 5 × 10−8) (Table 2 and Fig. 1). We observed no 
evidence of heterogeneity in allelic effects between the discovery and 
validation stages of the combined meta-analysis (Supplementary 
Table 5). As we expected, the new loci are characterized by lead SNPs 
that are relatively common in all ethnicities and have modest effects 
on T2D susceptibility that are homogeneous across ancestry groups 
(Supplementary Table 6). We did not harmonize adjustments for 
covariates within or between consortia because of variation in indi-
vidual study design and recorded non-genetic risk factors. However, 
we observed no evidence of heterogeneity in allelic effects in the 
European ancestry validation meta-analysis after stratification of 
the studies according to covariate adjustment (Online Methods and 
Supplementary Table 7). These data thus provide no evidence of bias 
in the allelic effect estimates at lead SNPs at the new loci and suggest 
our results to be robust to variability in correction for potential con-
founders across studies.
The new loci include SNPs mapping near POU5F1-TCF19 in the 
major histocompatibility complex (MHC), a region of the genome 
that is essential to the immune response. The MHC harbors HLA 
class II genes, which together account for approximately half of the 
genetic risk to type 1 diabetes (T1D)27. We observed no evidence of 
association of T2D with tags for traditional T1D HLA risk alleles in 
the trans-ethnic meta-analysis: HLA-DR4 (rs660895, P = 0.32) and 
HLA-DR3 (rs2187668, P = 0.34). Furthermore, when we considered 
lead SNPs at 49 T1D susceptibility loci (Supplementary Table 8), 
we observed nominal evidence of association (P < 0.05) with T2D 
and the same risk allele for both diseases at just two loci (GLIS3 and 
6q22.32) but not at that mapping to the MHC (rs9268645, P = 0.33). 
There is very strong evidence that T1D risk variants, particularly 
in the MHC, are also associated with latent autoimmune diabetes 
of adulthood (LADA)28,29, which is a late age–onset, more indolent 
form of the disease that often results in a clinical misdiagnosis of 
T2D. Although studies contributing to the trans-ethnic meta-analysis 
differed in the degree to which they were able to exclude cases 
with LADA, the lack of association of T1D risk variants suggests 
that the rates of diagnostic misclassification of autoimmune diabetes 
were too modest to drive the T2D GWAS signal at the POU5F1-
TCF19 locus.
The new loci also include SNPs mapping to ARL15 and SSR1-
RREB1, which have been implicated previously at genome-wide 
significance in the regulation of fasting insulin (FI) and fasting glu-
cose (FG), respectively30. The lead SNPs for T2D (rs702634) and FI 
(rs4865796) mapping to ARL15 are closely correlated in populations 
of European and east Asian ancestry (CEU r2 = 1.00 and CHB+JPT 
r2 = 0.87 from Phase II HapMap). However, the lead T2D SNP 
(rs9505118) is independent of that for FG (rs17762454) at the SSR1-
RREB1 locus (CEU and CHB+JPT r2 < 0.05). The ARL15 locus has 
also been associated with circulating levels of adiponectin, which is 
an adipocyte-secreted protein that has antidiabetic effects31, but the 
lead SNP (rs4311394) is independent of that for T2D susceptibility 
from the trans-ethnic meta-analysis.
To obtain a more comprehensive view of the overlap of the 
newly associated T2D susceptibility loci with metabolic pheno-
types, we interrogated published European ancestry meta-analyses 
from the Meta-Analysis of Glucose and Insulin-related traits 
Consortium (MAGIC) Investigators3,30, the Genetic Investigation 
of ANthropometric Traits (GIANT) Consortium32,33 and the Global 
Lipids Genetics Consortium34 to evaluate the effect of T2D risk alleles 
on glycemic traits, including homeostatic model of assessment indices 
of beta-cell function (HOMA-B) and insulin resistance (HOMA-IR); 
anthropometric measures; and plasma lipid concentrations (Online 
Methods and Supplementary Tables 9–11). T2D risk alleles at SSR1-
RREB1 and LPP have features that indicate a primary role in suscep-
tibility through beta-cell dysfunction: increased FG (P = 1.0 × 10−5 
and P = 8.6 × 10−7, respectively) and reduced HOMA-B (P = 0.11 and 
P = 0.011, respectively). Conversely, the T2D risk allele mapping to 
ARL15 is associated with increased FI, most strongly after adjustment 
for body mass index (BMI) (P = 5.0 × 10−12), and increased HOMA-IR 
(P = 0.021) and is thus more characteristic of action through insulin 
resistance. This risk allele is also associated with reduced levels of 
high-density lipoprotein cholesterol (P = 0.022) and increased levels 
of triglycerides (P = 0.010), as we expected, but also with reduced 
BMI (P = 5.6 × 10−5).
To identify the most promising functional candidate transcripts 
among those mapping to the new susceptibility loci, we interrogated 
public databases and unpublished resources for expression quantita-
tive trait loci (eQTL) from a variety of tissues (Online Methods). The 
lead T2D SNPs at three loci showed nominal association (P < 10−5) 
table 2 New t2D susceptibility loci achieving genome-wide significance (P < 5 × 10−8)
Locus Lead SNP Chr
Build 36  
position (bp)
Allelesa
Trans-ethnic discovery  
meta-analysis
European ancestry validation 
meta-analysis Combined meta-analysis
Risk Other OR (95% CI) P OR (95% CI) P OR (95% CI) P
TMEM154 rs6813195 4 153,739,925 C T 1.08 (1.05–1.11) 4.2 × 10−9 1.08 (1.05–1.11) 2.0 × 10−6 1.08 (1.06–1.10) 4.1 × 10−14
SSR1-RREB1 rs9505118 6 7,235,436 A G 1.06 (1.04–1.09) 1.9 × 10−6 1.06 (1.03–1.09) 1.7 × 10−4 1.06 (1.04–1.08) 1.4 × 10−9
FAF1 rs17106184 1 50,682,573 G A 1.11 (1.07–1.16) 1.9 × 10−6 1.09 (1.04–1.15) 4.8 × 10−4 1.10 (1.07–1.14) 4.1 × 10−9
POU5F1-TCF19 rs3130501 6 31,244,432 G A 1.07 (1.04–1.10) 1.5 × 10−6 1.06 (1.03–1.10) 7.0 × 10−4 1.07 (1.04–1.09) 4.2 × 10−9
LPP rs6808574 3 189,223,217 C T 1.08 (1.04–1.11) 4.3 × 10−6 1.06 (1.03–1.09) 2.6 × 10−4 1.07 (1.04–1.09) 5.8 × 10−9
ARL15 rs702634 5 53,307,177 A G 1.08 (1.05–1.11) 3.4 × 10−7 1.05 (1.02–1.08) 2.1 × 10−3 1.06 (1.04–1.09) 6.9 × 10−9
MPHOSPH9 rs4275659 12 122,013,881 C T 1.06 (1.03–1.09) 5.5 × 10−6 1.06 (1.02–1.09) 4.4 × 10−4 1.06 (1.04–1.08) 9.5 × 10−9
The T2D susceptibility loci shown were identified through trans-ethnic discovery-stage GWAS meta-analysis of 26,488 cases and 83,964 controls of European, east Asian, south 
Asian and Mexican and Mexican American ancestry with follow up in a validation-stage meta-analysis of an additional 21,491 cases and 55,647 controls of European ancestry 
genotyped with the Metabochip. Chr, chromosome; OR, odds ratio; CI, confidence interval.
aAlleles are aligned to the forward strand of NCBI Build 36.
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with expression and were in strong LD (CEU and CHB+JPT r2 > 0.8) 
with the reported cis-eQTL variant: SSR1 (B cells, P = 2.2 × 10−6) at 
the SSR1-RREB1 locus; ABCB9 (liver, P = 7.4 × 10−12) and SETD8 
(lung, P < 2.0 × 10−16) at the MPHOSPH9 locus; and HCG27 (mono-
cytes, P = 1.3 × 10−69) at the POU5F1-TCF19 locus (Supplementary 
Table 12).
We also evaluated new loci for potential functional mechanisms 
underlying T2D susceptibility (Online Methods). We identified vari-
ants for functional annotation in pilot data from the 1000 Genomes 
Project25 that are in strong LD (CEU and CHB+JPT r2 > 0.8) with the 
lead SNPs in the seven new susceptibility loci. We identified a mis-
sense variant at the POU5F1-TCF19 locus in TCF19 (rs113581344, 
p.Val211Met; CEU r2 = 0.96 and CHB+JPT r2 = 0.80 with lead 
SNP rs3130501), although it is predicted to be tolerated by SIFT35 
(Supplementary Table 13). Lead SNPs in the new susceptibility loci 
were also in strong LD with variants in the UTRs of SSR1 (at the 
SSR1-RREB1 locus) and ABCB9, OGFOD2 and PITPNM2 (at the 
MPHOSPH9 locus). Variants in strong LD with the lead SNPs at two 
of the new susceptibility loci overlap regions of predicted regulatory 
function generated by the ENCODE Project36 (Supplementary Fig. 2). 
The lead SNP at the LPP locus maps to an enhancer region that 
is active in HepG2 cells. We also identified a variant at the FAF1 
locus (rs58836765; CEU r2 = 0.89 and CHB+JPT r2 = 0.80 with lead 
SNP rs17106184) that overlaps a region of open chromatin activity 
in pancreatic islets and other cell types. This open chromatin site 
is in a region that is correlated with expression of ELAVL4, which 
has been demonstrated to regulate insulin translation in pancreatic 
beta cells37, highlighting this transcript as a credible candidate at the 
FAF1 locus. Regulatory annotations in HepG2 cells and pancreatic 
islets are both broadly enriched at T2D-associated variants38 and are 
thus supportive of these functional mechanisms for causal variant 
activity at both loci.
Improved	fine-mapping	resolution	at	T2D	susceptibility	loci
Given our observation that the causal variants underlying GWAS 
signals are shared across ancestry groups at many T2D susceptibility 
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Figure 1 Signal plots of the trans-ethnic discovery-stage GWAS meta-analysis for new T2D 
susceptibility loci. The trans-ethnic meta-analysis comprised 26,488 T2D cases and 83,964 
controls from populations of European, east Asian, south Asian and Mexican and Mexican 
American ancestry imputed up to 2.5 million Phase II/III HapMap autosomal SNPs. Each point 
represents a SNP passing quality control in the trans-ethnic meta-analysis plotted with its P value 
(on a −log10 scale) as a function of genomic position (NCBI Build 36). In each plot, the lead SNP 
is represented by the purple symbol. The color coding of all other SNPs indicates LD with the 
lead SNP (estimated by CEU r2 values from Phase II HapMap): red, r2 ≥ 0.8; gold, 0.6 ≤ r2 < 0.8; 
green, 0.4 ≤ r2 < 0.6; cyan, 0.2 ≤ r2 < 0.4; blue, r2 < 0.2; gray, r2 unknown. The shape of the 
plotting symbol corresponds to the annotation of the SNP: upward triangle for framestop or splice; 
downward triangle for nonsynonymous; square for synonymous or UTR; and circle for intronic or 
noncoding. Recombination rates are estimated from Phase II HapMap, and gene annotations are 
taken from the UCSC genome browser.
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loci, we evaluated the evidence for improved fine-mapping resolution 
through trans-ethnic meta-analysis. For this purpose, we combined 
association summary statistics from the ethnic-specific meta-analyses 
using MANTRA39. This Bayesian approach has the advantage of allow-
ing for heterogeneity in allelic odds ratios between ancestry groups 
arising as a result of differential patterns of LD with a shared underly-
ing causal variant across diverse populations, which cannot be accom-
modated in fixed-effects meta-analysis (Online Methods). Simulation 
studies have demonstrated improved detection and localization of 
causal variants through trans-ethnic meta-analysis with MANTRA 
compared to either a fixed- or random-effects model39,40.
Within each locus, we constructed credible sets41 of SNPs that are 
most likely to be causal on the basis of their statistical evidence of 
association from the MANTRA meta-analysis. Credible sets can be 
interpreted in a way similar to confidence intervals in a frequentist 
statistical framework. For example, assuming that a locus harbors a 
single causal variant that is reported in the meta-analysis, the prob-
ability that it will be contained in the 99% credible set is 0.99. Smaller 
credible sets, in terms of the number of SNPs they contain or the 
genomic interval they cover, thus correspond to fine mapping at 
higher resolution. It is essential that SNP coverage be as uniform as 
possible across studies in the construction of credible sets, otherwise 
differences in association signals between variants may reflect vari-
ability in sample sizes in the meta-analysis and not true differences 
in the magnitude of effects on T2D susceptibility. Consequently, we 
did not consider the European ancestry Metabochip validation studies 
in our fine-mapping analyses because the SNP density across the 
majority of T2D susceptibility loci on the array is too sparse to allow 
high-quality imputation up to the Phase II/III HapMap reference 
panels utilized in the trans-ethnic discovery GWAS.
In constructing credible sets, we assume that there is a single causal 
variant at each locus. However, there is increasing evidence that mul-
tiple association signals, typically characterized by independent com-
mon index SNPs, are relatively widespread at T2D susceptibility loci, 
for example CDKN2A-CDKN2B and KCNQ1 (ref. 6). Fine mapping 
of these independent association signals will require formal condi-
tioning, adjusting for genotypes at each index SNP in turn, before 
construction of the credible set for each underlying causal variant. 
Approximate conditioning, without formal computation, as imple-
mented in GCTA42 makes use of meta-analysis summary statistics 
and a reference panel to approximate LD between SNPs (and hence 
correlation between parameter estimates in a joint association model). 
Unfortunately, this approach is not feasible in a trans-ethnic context 
because of differences in LD structure between ancestry groups and 
thus could not be applied in this study. Consequently, the credible sets 
defined here correspond to fine mapping across association signals 
at each locus.
To assess the improvements in fine-mapping resolution by combin-
ing GWAS from diverse populations, we compared the properties of 
the MANTRA 99% credible set on the basis of association summary 
statistics from the European ancestry–only meta-analysis and the trans-
ethnic meta-analysis of European, east Asian, south Asian and Mexican 
and Mexican American ancestry groups. We focused on 10 autosomal 
loci (of the 69 previously established) that attained association with 
T2D susceptibility at genome-wide significance in the European ances-
try meta-analysis (Table 3). We did not consider loci with weaker sig-
nals of association, as they were typically characterized by large 99% 
credible sets in the European ancestry meta-analysis and thus might 
provide an overestimate of the improvement in fine-mapping resolution 
by combining GWAS across ancestry groups. Of the loci considered, 
only at MTNR1B did we not see any improvement in fine-mapping 
resolution in terms of the number of SNPs and the genomic interval 
covered by the 99% credible set after trans-ethnic meta-analysis.
We observed the greatest enhancement in fine-mapping resolu-
tion after trans-ethnic meta-analysis at the JAZF1 locus, where the 
genomic interval covered by the 99% credible set was reduced from 
76 kb to just 16 kb (Fig. 2 and Supplementary Fig. 3). Of the nine 
variants in the European 99% credible set, five were excluded after 
trans-ethnic meta-analysis because of low LD with the lead SNP at 
this locus in populations of east Asian ancestry (CHB+JPT r2 < 0.05 
with rs864745). Among the variants retained in the 99% credible set 
after trans-ethnic meta-analysis, interrogation of predicted regulatory 
function from the ENCODE Project36 showed that rs1635852 maps 
to a region of open chromatin with enhancer activity that is bound by 
several transcription factors. This SNP has been shown previously to 
have allelic differences in pancreatic islet enhancer activity43 and is 
also correlated with expression of CREB5, highlighting this transcript 
as a credible candidate at the JAZF1 locus.
We also observed a substantial reduction in the genomic inter-
val covered by the credible set at the SLC30A8 locus (Fig. 2 and 
Supplementary Fig. 3) from 35 kb (four SNPs) on the basis of the 
European ancestry GWAS only to less than 1 kb (two SNPs) after 
trans-ethnic meta-analysis. However, the lead SNP is strongly 
 correlated with all variants in the credible set before trans-ethnic 
meta-analysis in both the European and east Asian ancestry groups 
(CEU and CHB+JPT r2 ≥ 0.8 with rs13266634), suggesting that the 
improved fine-mapping resolution at this locus is more likely the 
result of increased sample size than differences in LD structure 
between the populations. Encouragingly, the lead SNP after trans-
ethnic meta-analysis is more clearly separated from the other SNPs 
table 3 Properties of the 99% credible sets of SNPs at ten established t2D susceptibility loci
Locus Chr
99% credible set: European ancestry meta-analysis 99% credible set: trans-ethnic meta-analysis 99% credible set: reduction
SNPs Interval (bp) Build 36 location (bp) SNPs Interval (bp) Build 36 location (bp) SNPs Interval (bp)
JAZF1 7 9 75,685 28,147,081–28,222,765 4 15,667 28,147,081–28,162,747 5 60,018
SLC30A8 8 4 35,488 118,253,964–118,289,451 2 243 118,253,964–118,254,206 2 35,245
CDKAL1 6 5 24,244 20,787,688–20,811,931 2 1,549 20,794,552–20,796,100 3 22,695
HHEX/IDE 10 8 19,195 94,452,862–94,472,056 2 937 94,455,539–94,456,475 6 18,258
TCF7L2 10 3 13,684 114,744,078–114,757,761 2 2,309 114,746,031–114,748,339 1 11,375
IGF2BP2 3 17 32,656 186,980,329–187,012,984 12 24,504 186,988,481–187,012,984 5 8,152
FTO 16 27 45,981 52,357,008–52,402,988 10 39,335 52,361,075–52,400,409 17 6,646
CDKN2A/B 9 3 2,019 22,122,076–22,124,094 1 1 22,122,076–22,122,076 2 2,018
PPARG 3 23 265,269 12,106,687–12,371,955 21 265,269 12,106,687–12,371,955 2 0
MTNR1B 11 15 55,032 92,307,378–92,362,409 15 55,032 92,307,378–92,362,409 0 0
The properties shown are based on association summary statistics from the meta-analysis of the European ancestry GWAS only (12,171 cases and 56,862 controls) and the  
trans-ethnic meta-analysis of European, east Asian, south Asian and Mexican and Mexican American ancestry GWAS (26,488 cases and 83,964 controls).
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in the credible set and is a nonsynonymous variant, p.Arg325Trp, that 
has an established functional role in T2D susceptibility44.
We next tested variants present in the 99% credible sets at the 
ten loci on the basis of the European ancestry GWAS only and the 
trans-ethnic meta-analysis for enrichment of functional annotation 
compared to randomly shifted element locations (Online Methods). 
Variants in the trans-ethnic 99% credible sets were significantly 
enriched (empirical P < 0.05) for overlap with DNaseI hypersen-
sitive sites (DHS P = 0.038) and transcription factor binding sites 
(TFBS P = 0.0060). However, we observed no such enrichment in 
either annotation category for the European ancestry 99% credible 
sets (DHS P = 0.18; TFBS P = 0.087). These data suggest that vari-
ants retained after trans-ethnic meta-analysis show greater potential 
for functional impact on T2D susceptibility through these regulatory 
mechanisms.
The fine-mapping intervals defined by credible sets after trans-
ethnic meta-analysis are limited by the density and allele frequency 
spectrum of the GWAS genotyping arrays and HapMap reference 
panels used for imputation. Although these reference panels pro-
vide comprehensive coverage of common SNPs (MAF > 5%) across 
ancestry groups, imputation up to phased haplotypes from the 1000 
Genomes Project25,45, for example, would allow assessment of the 
impact of lower-frequency variation on T2D susceptibility in diverse 
populations46–48. However, we have demonstrated that for a fixed 
reference panel, trans-ethnic meta-analysis can improve the localiza-
tion of common causal SNPs within established T2D susceptibility 
loci, and we have identified highly annotated variants within fine-
mapping intervals defined by the 99% credible sets. We have also 
assessed the sensitivity of the trans-ethnic fine-mapping analysis to 
genotype quality at directly typed or imputed SNPs (Supplementary 
Table 14). We repeated MANTRA fine mapping with subsets of 
SNPs that passed quality control in at least 80% (n = 88,361) or 90% 
(n = 99,406) of individuals from the trans-ethnic meta-analysis. As 
the threshold for the reported sample size increased, the number 
of SNPs included in the fine-mapping analysis was reduced, but 
the genomic intervals covered by the 99% credible sets remained 
unchanged, suggesting the resolution to be relatively robust to geno-
type quality at common variants.
DISCUSSION
We have identified seven new loci for T2D susceptibility at genome-
wide significance by combining GWAS from multiple ancestry groups. 
Our study has provided evidence of many more common variant loci 
not yet reaching genome-wide significance that contribute to the 
heritability of T2D susceptibility, which is in agreement with poly-
genic analyses in European ancestry GWAS5,49. The effects of these 
common variants are modest but are homogeneous across ancestry 
groups and would thus be amenable to discovery through trans-
ethnic meta-analysis in larger samples. We have also demonstrated 
improvements in the resolution of fine mapping of common variant 
association signals through trans-ethnic meta-analysis, even in the 
absence of GWAS of African ancestry, which would be expected to 
better refine localization because of reduced LD in these populations. 
Future releases of reference panels from the 1000 Genomes Project are 
anticipated to comprise 2,500 samples, including haplotypes of south 
Asian ancestry and a wider representation of populations of African 
descent. This panel will provide a comprehensive catalog of genetic 
variation with MAFs as low as 0.5%, as well as many rarer variants, 
across major ancestry groups, thus facilitating imputation and cover-
age of loci for future trans-ethnic fine-mapping efforts.
Our analyses clearly highlight the benefits of combining GWAS 
from multiple ancestry groups for discovery and characterization of 
common variant loci contributing to complex traits and emphasize 
an exciting opportunity to further our understanding of the biologi-
cal mechanisms underlying human diseases across populations from 
diverse ethnicities.
METhODS
Methods and any associated references are available in the online 
version of the paper.
Figure 2 Signal plots presenting 99% credible 
sets of SNPs at the JAZF1 and SLC30A8 loci. 
The credible sets were constructed on the basis 
of the meta-analysis of European ancestry  
GWAS only (12,171 cases and 56,862  
controls) and the trans-ethnic meta-analysis of 
European, east Asian, south Asian and  
Mexican and Mexican American ancestry  
GWAS (26,488 cases and 83,964 controls).  
In each plot, each point represents a SNP 
passing quality control in the MANTRA  
analysis plotted with its Bayes’ factor (on a 
log10 scale) as a function of genomic position 
(NCBI Build 36). The lead SNP is represented 
by the purple symbol. The color coding of all 
other SNPs indicates LD with the lead SNP  
(estimated by Phase II HapMap CEU r2 values 
for the European ancestry meta-analysis and 
CHB+JPT for the trans-ethnic meta-analysis  
to highlight differences in structure  
between ancestry groups): red, r2 ≥ 0.8; gold, 
0.6 ≤ r2 < 0.8; green, 0.4 ≤ r2 < 0.6; cyan,  
0.2 ≤ r2 < 0.4; blue, r2 < 0.2; gray, r2 unknown. 
The shape of the plotting symbol corresponds to 
the annotation of the SNP: upward triangle for 
framestop or splice; downward triangle for nonsynonymous; square for synonymous or UTR; and circle for intronic or noncoding. Recombination  
rates are estimated from Phase II HapMap, and gene annotations are taken from the UCSC genome browser. The genomic region covered by the 99% 
credible set is highlighted in gray.
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Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE	METhODS
Ancestry-specific GWAS meta-analyses. Ancestry-specific meta-analyses 
have been previously performed by the DIAGRAM Consortium (12,171 cases 
and 56,862 controls; European ancestry)5; the AGEN-T2D Consortium (6,952 
cases and 11,865 controls; east Asian ancestry)11; the SAT2D Consortium 
(5,561 cases and 14,458 controls; south Asian ancestry)13; and the MAT2D 
Consortium (1,804 cases and 779 controls; Mexican and Mexican American 
ancestry)15. Further details of the samples and methods employed within each 
ancestry group are presented in the corresponding consortium papers5,11,13,15. 
Briefly, individuals were assayed with a range of genotyping products, 
with sample and SNP quality control (QC) undertaken within each study 
(Supplementary Tables 1 and 2). Each GWAS scaffold was imputed up to 2.5 
million autosomal SNPs using reference panels from Phase II/III HapMap22,23 
(Supplementary Table 2). Each SNP with MAF > 1%, (or MAF > 5% in the 
Mexican and Mexican American ancestry GWAS because of smaller sample 
size) and passing QC was tested for association with T2D under an additive 
model after adjustment for study-specific covariates (Supplementary Table 2). 
Covariate adjustments were not harmonized within or between consortia 
because of variation in study design and recorded non-genetic risk factors. The 
results of each GWAS were corrected for population structure with genomic 
control50 (unless λGC < 1). Association summary statistics from GWAS within 
each ancestry group were then combined by fixed-effects meta-analysis. 
The results of each ethnic-specific meta-analysis were then corrected by a second 
round of genomic control: European ancestry (λGC = 1.10); east Asian ancestry 
(λGC = 1.05); south Asian ancestry (λGC = 1.02); Mexican and Mexican 
American ancestry (λGC = 1.01).
Trans-ethnic discovery-stage GWAS meta-analysis. Association summary 
statistics from each ancestry-specific meta-analysis were combined in a fixed-
effects inverse-variance–weighted meta-analysis (in a total of 26,488 cases and 
83,964 controls). The association results of the trans-ethnic meta-analysis were 
corrected by genomic control50 (λGC = 1.05).
Heterogeneity analyses. For each previously reported lead SNP at an estab-
lished T2D susceptibility locus, we assessed heterogeneity in allelic effects 
between the ethnic-specific meta-analyses by means of Cochran’s Q statistic51 
(Supplementary Table 3). Among the 52 SNPs passing QC in all four ethnic-
specific meta-analyses, we identified those that showed the same direction of 
effect across all ancestry groups and evaluated the significance of the excess 
in concordance (12.5% expected) with a one-sided binomial test.
Concordance analyses. We identified SNPs passing QC and with MAF > 
1% in all four ethnic-specific meta-analyses. We excluded variants in the 69 
established autosomal T2D susceptibility loci, defined as 500 kb upstream and 
500 kb downstream of the previously reported lead SNPs. We also excluded 
AT/GC SNPs to eliminate bias due to strand misalignment between ethnic-
specific meta-analyses. Among the remaining SNPs, we selected an independ-
ent subset with nominal evidence of association (P ≤ 0.001) with T2D from 
the European ancestry meta-analysis and separated by at least 500 kb. For 
each independent SNP, we identified the T2D risk allele from the European 
ancestry meta-analysis and determined the direction of effect in the east Asian, 
south Asian and Mexican and Mexican American ancestry meta-analyses. 
We calculated the proportion of these SNPs that had the same direction of 
effect for the European ancestry risk allele and the significance of the excess 
in concordance (50% expected) with a one-sided binomial test. We repeated 
this analysis for SNPs with weaker evidence of association with T2D from the 
European ancestry meta-analysis: 0.001 < P ≤ 0.01; 0.01 < P ≤ 0.5; and 0.5 < 
P ≤ 1 (Table 1). We then repeated these analyses using the east Asian, south 
Asian and Mexican and Mexican American ancestry meta-analyses, in turn, 
to identify subsets of independent T2D risk alleles and assessed concordance 
into the other ethnic groups (Supplementary Table 4).
European ancestry validation-stage meta-analysis. The previously pub-
lished validation meta-analysis consisted of 21,491 cases and 55,647 controls 
of European ancestry from the DIAGRAM Consortium5, all genotyped with 
the Metabochip26 (Supplementary Table 1). We excluded the Pakistan Risk 
Of Myocardial Infarction Study (PROMIS) from the validation meta-analysis 
to avoid overlap with a subset of the same individuals contributing to the 
SAT2D Consortium meta-analysis13. Full details of the samples and methods 
employed in the validation meta-analysis are presented in the DIAGRAM 
Consortium paper5. Briefly, sample and SNP QC were undertaken within 
each study (Supplementary Table 2). Each high-quality SNP (MAF > 1%) 
was tested for association with T2D under an additive model after adjustment 
for study-specific covariates (Supplementary Table 2). Association summary 
statistics for each study were corrected using the genomic control inflation 
factor obtained from a subset of 3,598 ‘QT interval’ replication SNPs5,26 (unless 
λQT < 1). These statistics were then combined in a fixed-effects inverse- 
variance–weighted meta-analysis and were corrected by a second round of 
genomic control (λQT = 1.19).
Combined meta-analysis. We selected lead SNPs at 33 new loci with sug-
gestive evidence of association (P < 10−5) from the trans-ethnic discovery 
GWAS meta-analysis for in silico follow up in the European ancestry validation 
meta-analysis. Of these SNPs, 16 were genotyped directly on Metabochip, and 
10 more had a proxy (CEU and CHB+JPT HapMap r2 ≥ 0.2). For these 26 SNPs, 
association summary statistics from the discovery and validation meta-analy-
ses were combined in a fixed-effects inverse-variance–weighted meta-analysis 
(Supplementary Table 5). The combined meta-analysis consisted of 47,979 
T2D cases and 139,611 controls. Heterogeneity in allelic effects between the 
two stages of the combined meta-analysis was assessed by means of Cochran’s 
Q statistic51.
Sensitivity to covariate adjustment. We identified 19 studies (11,327 cases 
and 31,342 controls) from the European ancestry validation meta-analysis 
that adjusted for only age, sex (unless male or female specific) and popula-
tion structure where necessary (Supplementary Table 2): AMC-PAS; BHS; 
DILGOM; EAS; EGCUT; EMIL-ULM; EPIC; FUSION Stage 2; D2D2007; Dr’s 
Extra; HUNT; METSIM (male specific); HNR; IMPROVE; KORAGen Stage 2; 
PIVUS; THISEAS; ULSAM (male specific); and WARREN2. Association 
summary statistics from each of these studies were then combined in a fixed-
effects inverse-variance–weighted meta-analysis, the results of which were 
subsequently corrected for genomic control (λQT = 1.12). The remaining six 
studies (10,164 cases and 24,305 controls) did not adjust for age and/or sex or 
included additional covariates to account for BMI or cardiovascular-related 
disease status (Supplementary Table 2): deCODE Stage 2; DUNDEE; GMetS; 
PMB; SCARFSHEEP; and STR. Association summary statistics from each of 
these studies were then combined in a fixed-effects inverse-variance–weighted 
meta-analysis but did not require subsequent correction for genomic control 
(λQT = 1.00). We then tested for heterogeneity in allelic effects between these two 
sets of studies by means of Cochran’s Q statistic51 (Supplementary Table 7).
Association of lead T1D SNPs with T2D. We obtained association sum-
mary statistics with T2D from the trans-ethnic meta-analysis for previously 
reported lead SNPs in established T1D susceptibility loci27 (Supplementary 
Table 8). For each SNP, we aligned the allelic effect on T2D according to 
the risk allele for T1D (where reported). We also obtained association sum-
mary statistics for tags for T1D HLA risk alleles: HLA-DR4 (rs660895) and 
HLA-DR3 (rs2187668).
Association of lead T2D SNPs with metabolic traits. We obtained associa-
tion summary statistics (P values, directed Z scores and/or allelic effects and 
corresponding standard errors) for lead SNPs at new T2D susceptibility loci in 
published European ancestry GWAS meta-analyses of metabolic phenotypes: 
glycemic traits3,30, anthropometric measures32,33 and plasma lipid concentra-
tions34. We considered glycemic traits in non-diabetic individuals from the 
MAGIC Investigators (Supplementary Table 9). For FG and FI concentrations 
(with and without adjustment for BMI), the meta-analysis consisted of up to 
133,010 and 108,557 individuals, respectively. For HOMA-B and HOMA-IR, 
the meta-analysis consisted of up to 37,037 individuals. We considered anthro-
pometric measures from the GIANT Consortium (Supplementary Table 10). 
For BMI and waist-hip ratio adjusted for BMI, the meta-analysis consisted of 
123,865 and 77,167 individuals, respectively. We then considered plasma lipid 
concentrations from the Global Lipids Genetics Consortium (Supplementary 
Table 11). For total cholesterol, high-density lipoprotein cholesterol, low-density 
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lipoprotein cholesterol and triglycerides, the meta-analysis consisted of up to 
100,184 individuals.
Expression analyses. We interrogated public databases and unpublished 
resources for cis-eQTL expression with lead SNPs in the new susceptibil-
ity loci in multiple tissues. Details of these resources are summarized in the 
Supplementary Note. The collated results from these resources met study-
specific criteria for statistical significance for association with expression. For 
each transcript associated with the lead T2D SNP (Supplementary Table 12), 
we identified the cis-eQTL SNP with the strongest association with expression 
in the same tissue and subsequently estimated the LD between them using 
pilot data from the 1000 Genomes Project25 (CEU and CHB+JPT) to assess 
the coincidence of the signals.
Functional annotation. We identified variants in pilot data from the 1000 
Genomes Project25 that are in strong LD (CEU and CHB+JPT r2 > 0.8) with the 
lead SNPs in the new susceptibility loci for functional annotation. Identified 
nonsynonymous variants were interrogated for likely downstream functional 
consequences using SIFT35 (Supplementary Table 13). Variants were also 
assessed for overlap with regions of predicted regulatory function generated 
by the ENCODE Project36 including: ChromHMM regulatory state definitions 
from 9 cell lines (GM12878, HepG2, HUVEC, HMEC, HSMM, K562, NHLF, 
NHEK and hESC); transcription factor binding ChIP sites from 95 cell types; 
open chromatin (DNaseI hypersensitivity) sites from 125 cell types; tran-
scripts correlated with open chromatin site activity; and sequence motifs from 
JASPAR, TRANSFAC and de novo prediction (Supplementary Fig. 2).
Fine-mapping analyses. We used MANTRA39 to fine-map T2D susceptibil-
ity loci on the basis of association summary statistics from the meta-analysis 
of European ancestry GWAS only5 and the trans-ethnic meta-analysis of 
European, east Asian, south Asian and Mexican and Mexican American 
 ancestry GWAS5,11,13,15. MANTRA allows for trans-ethnic heterogene-
ity in allelic effects arising as a result of differences in the structure of LD 
with the causal variant in diverse populations by assigning ancestry groups 
to ‘clusters’ according to a Bayesian partition model of relatedness between 
them, as defined by pairwise genome-wide mean allele frequency differences 
(Supplementary Fig. 4). Evidence in favor of association of each SNP with 
T2D is measured by a Bayes’ factor (BF). We assume a single causal variant 
for T2D at each locus (defined by the region 500 kb upstream and 500 kb 
downstream of the lead SNP from the trans-ethnic meta-analysis). We then 
calculated the posterior probability that the jth SNP is causal among those 
reported in the meta-analysis:
j j
j
kk
BF
BF
= ∑
In this expression, BFj denotes the BF in favor of association of the jth SNP, 
and the summation in the denominator is over all variants passing QC across 
the locus41. A 99% credible set of variants was then constructed by ranking all 
SNPs according to their BF and combining ranked SNPs until their cumulative 
posterior probability exceeds 0.99.
SNPs in the 99% credible sets were assessed for enrichment in ChromHMM 
regulatory state (enhancer, promoter and insulator), DNaseI hypersensitive 
and transcription factor binding sites using data from the ENCODE Project36. 
We performed 1,000 permutations by shifting the location of the annotation 
sites a random distance within 100 kb and recalculated the overlap to obtain 
empirical P values for enrichment in each annotation category.
50. Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55, 
997–1004 (1999).
51. Ioannidis, J.P. et al. Heterogeneity in meta-analyses of genome-wide association 
investigations. PLoS ONE 2, e841 (2007).
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